Literature DB >> 18997056

A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.

Joong-Won Park1, Ji Hoon Kim, Seok Ki Kim, Keon Wook Kang, Kyung Woo Park, Jun-Il Choi, Woo Jin Lee, Chang-Min Kim, Byung Ho Nam.   

Abstract

UNLABELLED: Because (18)F-FDG PET has insufficient sensitivity for the detection of hepatocellular carcinoma (HCC), (11)C-acetate PET has been proposed as another technique for this use. We prospectively evaluated the value of PET/CT using these 2 tracers for the detection of primary and metastatic HCC.
METHODS: One hundred twelve patients (99 with HCC, 13 with cholangiocellular carcinoma) underwent biopsy and (18)F-FDG and (11)C-acetate PET/CT.
RESULTS: The overall sensitivities of (18)F-FDG, (11)C-acetate, and dual-tracer PET/CT in the detection of 110 lesions in 90 patients with primary HCC were 60.9%, 75.4%, and 82.7%, respectively. Elevated serum alpha-fetoprotein levels, an advanced tumor stage, portal vein tumor thrombosis, large tumors, and multiple tumors were significantly associated with positive (18)F-FDG PET/CT results. Uptake of (11)C-acetate was associated with large and multiple tumors. For (18)F-FDG, the sensitivities according to tumor size (1-2, 2-5, and >/=5 cm) were 27.2%, 47.8%, and 92.8%, respectively; for (11)C-acetate, these respective values were 31.8%, 78.2%, and 95.2%. (18)F-FDG was more sensitive in the detection of poorly differentiated HCC. Overall survival was lower in patients with (18)F-FDG PET/CT positive for all indexed lesions than in those with FDG negative or partially positive through the entire follow-up period. In analysis based on biopsied lesions, the sensitivity of (18)F-FDG PET/CT was 64.4% for primary HCC and 84.4% for (11)C-acetate PET/CT. The overall sensitivities of (18)F-FDG, (11)C-acetate, and dual-tracer PET/CT for 35 metastatic HCCs were 85.7%, 77.0%, and 85.7%, respectively. There was no significant difference in the sensitivity of tracers according to metastatic tumor size, location, or differentiation.
CONCLUSION: The addition of (11)C-acetate to (18)F-FDG PET/CT increases the overall sensitivity for the detection of primary HCC but not for the detection of extrahepatic metastases. (18)F-FDG, (11)C-acetate, and dual-tracer PET/CT have a low sensitivity for the detection of small primary HCC, but (18)F-FDG PET/CT has a relatively high sensitivity for the detection of extrahepatic metastases of HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997056     DOI: 10.2967/jnumed.108.055087

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  88 in total

Review 1.  [Combined PET-MRI of the abdomen].

Authors:  Tibor Vag; M Eiber; M Schwaiger
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

2.  The effect of fasting on PET Imaging of Hepatocellular Carcinoma.

Authors:  Nathan Tenley; David J Corn; Lewis Yuan; Zhenghong Lee
Journal:  J Cancer Ther       Date:  2013-04

3.  Evaluation of hepatocellular carcinoma with portal vein tumor thrombosis by CEUS before and after hepatic arterial infusion chemotherapy.

Authors:  Hiroyuki Kirikoshi; Satoru Saito; Norio Ueno; Kaori Suzuki; Hirokazu Takahashi; Masato Yoneda; Koji Fujita; Atsushi Nakajima
Journal:  J Med Ultrason (2001)       Date:  2010-04-10       Impact factor: 1.314

4.  An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Wenjie Miao; Pei Nie; Guangjie Yang; Yangyang Wang; Lei Yan; Yujun Zhao; Ting Yu; Mingming Yu; Fengyu Wu; Wei Rao; Zhenguang Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-04       Impact factor: 9.236

Review 5.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

6.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

7.  Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation?

Authors:  Richard S Young; Mohammed Aldiwani; Abdul R Hakeem; Amit Nair; Ashley Guthrie; Judy Wyatt; Darren Treanor; Gareth Morris-Stiff; Rebecca L Jones; K Rajendra Prasad
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

8.  Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment.

Authors:  Chun-Yi Wu; Lin-Shan Chou; Pei-Chia Chan; Chung-Hsien Ho; Ming-Hsien Lin; Chih-Chieh Shen; Ren-Shyan Liu; Wuu-Jyh Lin; Hsin-Ell Wang
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

9.  Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.

Authors:  Maria-Angéla Castilla-Lièvre; Dominique Franco; Philippe Gervais; Bertrand Kuhnast; Hélène Agostini; Lysiane Marthey; Serge Désarnaud; Badia-Ourkia Helal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-18       Impact factor: 9.236

Review 10.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.